FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110335058> ?p ?o ?g. }

• W2110335058 endingPage "208" @default.
• W2110335058 startingPage "202" @default.
• W2110335058 abstract "The impact of pretransplant (hematopoietic cell transplantation [HCT]) cytarabine consolidation therapy on post-HCT outcomes has yet to be evaluated after reduced-intensity or nonmyeloablative conditioning. We analyzed 604 adults with acute myeloid leukemia in first complete remission (CR1) reported to the Center for International Blood and Marrow Transplant Research who received a reduced-intensity or nonmyeloablative conditioning HCT from an HLA-identical sibling, HLA-matched unrelated donor, or umbilical cord blood donor from 2000 to 2010. We compared transplant outcomes based on exposure to cytarabine postremission consolidation. Three-year survival rates were 36% (95% confidence interval [CI], 29% to 43%) in the no consolidation arm and 42% (95% CI, 37% to 47%) in the cytarabine consolidation arm (P = .16). Disease-free survival was 34% (95% CI, 27% to 41%) and 41% (95% CI, 35% to 46%; P = .15), respectively. Three-year cumulative incidences of relapse were 37% (95% CI, 30% to 44%) and 38% (95% CI, 33% to 43%), respectively (P = .80). Multivariate regression confirmed no effect of consolidation on relapse, disease-free survival, and survival. Before reduced-intensity or nonmyeloablative conditioning HCT, these data suggest pre-HCT consolidation cytarabine does not significantly alter outcomes and support prompt transition to transplant as soon as morphologic CR1 is attained. If HCT is delayed while identifying a donor, our data suggest that consolidation does not increase transplant treatment-related mortality and is reasonable if required." @default.
• W2110335058 created "2016-06-24" @default.
• W2110335058 creator A5001602966 @default.
• W2110335058 creator A5001697191 @default.
• W2110335058 creator A5003097876 @default.
• W2110335058 creator A5003369543 @default.
• W2110335058 creator A5011386306 @default.
• W2110335058 creator A5013398931 @default.
• W2110335058 creator A5017044459 @default.
• W2110335058 creator A5019979915 @default.
• W2110335058 creator A5021731378 @default.
• W2110335058 creator A5026151069 @default.
• W2110335058 creator A5026849709 @default.
• W2110335058 creator A5029278364 @default.
• W2110335058 creator A5029390145 @default.
• W2110335058 creator A5034779401 @default.
• W2110335058 creator A5035342920 @default.
• W2110335058 creator A5036295405 @default.
• W2110335058 creator A5037454036 @default.
• W2110335058 creator A5041346359 @default.
• W2110335058 creator A5042915360 @default.
• W2110335058 creator A5042974681 @default.
• W2110335058 creator A5052595717 @default.
• W2110335058 creator A5058862489 @default.
• W2110335058 creator A5059797628 @default.
• W2110335058 creator A5061692821 @default.
• W2110335058 creator A5062103615 @default.
• W2110335058 creator A5062116571 @default.
• W2110335058 creator A5066224233 @default.
• W2110335058 creator A5066238218 @default.
• W2110335058 creator A5067926047 @default.
• W2110335058 creator A5069685528 @default.
• W2110335058 creator A5070132319 @default.
• W2110335058 creator A5071407391 @default.
• W2110335058 creator A5071416130 @default.
• W2110335058 creator A5073620732 @default.
• W2110335058 creator A5076550283 @default.
• W2110335058 creator A5085360755 @default.
• W2110335058 creator A5085514831 @default.
• W2110335058 creator A5088486180 @default.
• W2110335058 creator A5088647781 @default.
• W2110335058 creator A5088962035 @default.
• W2110335058 date "2014-02-01" @default.
• W2110335058 modified "2023-10-15" @default.
• W2110335058 title "Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission" @default.
• W2110335058 cites W1492609361 @default.
• W2110335058 cites W1979299894 @default.
• W2110335058 cites W1987350756 @default.
• W2110335058 cites W2005499564 @default.
• W2110335058 cites W2007990409 @default.
• W2110335058 cites W2012548375 @default.
• W2110335058 cites W2036749000 @default.
• W2110335058 cites W2060342748 @default.
• W2110335058 cites W2064967925 @default.
• W2110335058 cites W2074425311 @default.
• W2110335058 cites W2087591188 @default.
• W2110335058 cites W2103628120 @default.
• W2110335058 cites W2107810465 @default.
• W2110335058 cites W2116435723 @default.
• W2110335058 cites W2118322536 @default.
• W2110335058 cites W2122587491 @default.
• W2110335058 cites W2144395887 @default.
• W2110335058 cites W2152197116 @default.
• W2110335058 cites W2155349260 @default.
• W2110335058 cites W2167638087 @default.
• W2110335058 cites W2167765664 @default.
• W2110335058 cites W2318674152 @default.
• W2110335058 cites W4293241248 @default.
• W2110335058 doi "https://doi.org/10.1016/j.bbmt.2013.10.023" @default.
• W2110335058 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3924751" @default.
• W2110335058 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24184335" @default.
• W2110335058 hasPublicationYear "2014" @default.
• W2110335058 type Work @default.
• W2110335058 sameAs 2110335058 @default.
• W2110335058 citedByCount "30" @default.
• W2110335058 countsByYear W21103350582014 @default.
• W2110335058 countsByYear W21103350582015 @default.
• W2110335058 countsByYear W21103350582016 @default.
• W2110335058 countsByYear W21103350582017 @default.
• W2110335058 countsByYear W21103350582018 @default.
• W2110335058 countsByYear W21103350582019 @default.
• W2110335058 countsByYear W21103350582020 @default.
• W2110335058 countsByYear W21103350582021 @default.
• W2110335058 countsByYear W21103350582022 @default.
• W2110335058 crossrefType "journal-article" @default.
• W2110335058 hasAuthorship W2110335058A5001602966 @default.
• W2110335058 hasAuthorship W2110335058A5001697191 @default.
• W2110335058 hasAuthorship W2110335058A5003097876 @default.
• W2110335058 hasAuthorship W2110335058A5003369543 @default.
• W2110335058 hasAuthorship W2110335058A5011386306 @default.
• W2110335058 hasAuthorship W2110335058A5013398931 @default.
• W2110335058 hasAuthorship W2110335058A5017044459 @default.
• W2110335058 hasAuthorship W2110335058A5019979915 @default.
• W2110335058 hasAuthorship W2110335058A5021731378 @default.
• W2110335058 hasAuthorship W2110335058A5026151069 @default.
• W2110335058 hasAuthorship W2110335058A5026849709 @default.
• W2110335058 hasAuthorship W2110335058A5029278364 @default.
• W2110335058 hasAuthorship W2110335058A5029390145 @default.

• next